Comparison of prognostic models in advanced hepatocellular carcinoma patients undergoing Sorafenib: A multicenter study.

Sorafenib is the gold standard therapy for the advanced hepatocellular carcinoma (HCC). No scoring/staging is universally accepted to predict the survival of these patients.

Source: Digestive and Liver Disease - December 19, 2020 Category: Gastroenterology Authors: Giovanni Marasco, Antonio Colecchia, Maria Letizia Bacchi Reggiani, Ciro Celsa, Fabio Farinati, Edoardo Giovanni Giannini, Francesca Benevento, Gian Ludovico Rapaccini, Eugenio Caturelli, Mariella Di Marco, Elisabetta Biasini, Fabio Marra, Filomena Morisc Tags: Liver, pancreas and biliary tract Source Type: research